
    
      Randomized, open label, multicenter, phase III clinical trial. Number of subjects: 104. Age
      range: 18 - 55 years of both sex.

      Timepoints for evaluation: Every two weeks, during the first six months after initiation of
      treatment discontinuation/continuation. Every four weeks during the remaining six months, to
      complete a total follow-up scheme of 12 months.
    
  